Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 09 2022 - 7:00AM
Business Wire
Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical
company developing and commercializing unique therapies for patient
populations in endocrinology, neurology, and gastroenterology,
today announced that Paul R. Edick, Chairman and CEO of Xeris
Biopharma, will participate in a fireside chat at the 11th Annual
SVB Leerink Global Healthcare Conference on Wednesday, February 16,
2022 at 12:00pm Eastern Time. A live webcast of the fireside chat
will be available on the investor relations section of the
Company's website at www.xerispharma.com.
About Xeris Biopharma
Xeris (Nasdaq: XERS) is a biopharmaceutical company developing
and commercializing unique therapies for patient population in
endocrinology, neurology, and gastroenterology. Xeris has three
commercially available products: Gvoke®, a ready-to-use liquid
glucagon for the treatment of severe hypoglycemia; Keveyis®, the
first and only FDA-approved therapy for primary periodic paralysis;
and Recorlev® for the treatment of endogenous Cushing’s syndrome.
Xeris also has a robust pipeline of development programs to extend
the current marketed products into important new indications and
uses and bring new products forward using its proprietary
formulation technology platforms, XeriSol™ and XeriJect™,
supporting long-term product development and commercial
success.
Xeris is headquartered in Chicago, IL. For more information,
visit www.xerispharma.com, or follow us on Twitter, LinkedIn or
Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220209005146/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Jul 2023 to Jul 2024